Trade Vir Biotechnology ^VIR

Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts

Why Vir Biotechnology (VIR) Is Up 5.1% After Astellas Cancer Deal And Equity Raise News

Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $20.00 - Zolmax

Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - Daily Political

Weekly Analysts' Ratings Changes for Vir Biotechnology (VIR) - Daily Political

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - Markets Daily

Vir Biotechnology Inc. (VIR) - Insider Monkey

Reviewing Werewolf Therapeutics (NASDAQ:HOWL) and Vir Biotechnology (NASDAQ:VIR) - Daily Political

Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,400.48 in Stock - Markets Daily

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

Why Vir Biotechnology (VIR) Is Up 20.2% After Astellas Deal And $150 Million Equity Raise

Vir Biotechnology (NASDAQ:VIR) EVP Sells $33,115.25 in Stock - Markets Daily

Vir Biotechnology (NASDAQ:VIR) EVP Mark Eisner Sells 1,616 Shares - Daily Political

Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 1,889 Shares of Stock

Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares

Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 13,700 Shares

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 42,377 Shares

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 42,377 Shares of Stock - Markets Daily

Company Website: https://vir.bio SAN FRANCISCO -- (Busines

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - Stock Observer

Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Should You Sell?

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Three Biotechs With the Right Formula - TheStreet Pro

Vir Biotechnology (NASDAQ:VIR) Sees Strong Trading Volume Following Analyst Upgrade - Markets Daily

Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.11 EPS - Stock Observer

A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CAO Sells 1,829 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock

Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Assessing Vir Biotechnology (VIR) Valuation After A Strong Year To Date Share Price Rebound

Vir Biotechnology (NASDAQ:VIR) CEO Sells $141,840.55 in Stock - Stock Observer

5 Stocks I'm Buying While the Crowd Focuses on AI Disaster - TheStreet Pro

Anthropic expands Claude AI chatbot, Keurig Dr Pepper's Q4 beat

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat

Promising Small Cap Stocks To Follow Now - February 24th - Stock Observer

Vir Biotech Soars On Global Collaboration With Astellas, Encouraging Prostate Cancer Drug Data

Vir Biotechnology Shares Jump Over 50% After Positive Phase 1 VIR-5500 Prostate Cancer Data

Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...

Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS

Vir Biotechnology Q4 Earnings Call Highlights - Stock Observer

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Morningstar

Astellas and Vir Biotechnology Announce Global Strategic Col

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Morningstar

Japan's Astellas announces $1.37 B deal with Vir Biotechnology to develop T-Cell therapies for prostate cancer

AI Podcast: Dollar Weakness and Investment Implications

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

Turkey's $500 Billion Gold Hoard: Unlocking Economic Potential

Brazil-US Tariffs: Trump's Intervention and Lula's Response

AI Podcast: US & Israel's Disagreements on Iran and Gaza

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

US Government Shutdown: Economic Fallout and Political Impasse

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

Fed's Rate Cut Conundrum: An Outlook to 2026